title: Efficacy and tolerance of liposomal daunorubicin in Kaposi sarcoma associated with human immunodeficiency virus infection.
authors.forename: S
authors.initials: S
authors.lastname: Fournier
authors.forename: B
authors.initials: B
authors.lastname: Dupont
authors.forename: G
authors.initials: G
authors.lastname: Pialoux
authors.forename: M
authors.initials: M
authors.lastname: Eliaszewicz
authors.forename: G
authors.initials: G
authors.lastname: Gonzalez-Canali
authors.forename: V
authors.initials: V
authors.lastname: Feuillie
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D018791:CD4 Lymphocyte Count; D003630:Daunorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004067:Digestive System Neoplasms / Q000188:drug therapy; D018450:Disease Progression; D004337:Drug Carriers; D006801:Humans; D008081:Liposomes; D008175:Lung Neoplasms / Q000188:drug therapy; D012074:Remission Induction; D012514:Sarcoma, Kaposi / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy; D015996:Survival Rate
chemical_list: D000903:Antibiotics, Antineoplastic; D004337:Drug Carriers; D008081:Liposomes; D003630:Daunorubicin